|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taken together, the ERBB3 kinase activity contributes to the outgrowth of ileal organoids and intestinal tumorigenesis, and the development of ERBB3 kinase inhibitors, including epidermal growth factor receptor family members, can be a potential way to target colorectal cancer.
|
31724799 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, certain classical tumor pathways were also activated by target genes, among which, lncRNA MSTRG.1056.2 directly regulates ERBB3 to activate the PI3K-Akt pathway, contributing to tumorigenesis.
|
31518640 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Dysregulation of ERBB3 trafficking as well as cooperation with other receptor tyrosine kinases further enhance ERBB3's role in tumorigenesis and drug resistance.
|
31351986 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Numerous studies have indicated that ErbB3 binding protein 1 (Ebp1), a binding partner for ErbB3, plays an important regulatory role in the expression and function of ErbB3, but there is no agreement as to whether Ebp1 also has an ErbB3-independent function in cancer and how it might contribute to tumorigenesis.
|
30076717 |
2018 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Current evidence suggests that HER2-driven tumorigenesis requires HER3.
|
29760043 |
2018 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We additionally show that ERAS synergistically enhances HER2-induced tumorigenesis and, in this role, can functionally replace ERBB3/HER3 by acting as a more powerful activator of PI3K/AKT signaling.
|
29326437 |
2018 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Anti-HER3 CD4+ Th1 responses decline during breast tumorigenesis, particularly in TNBC.
|
27663569 |
2017 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.
|
27517321 |
2016 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers.
|
26420857 |
2016 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our findings offer compelling evidence that APIP plays an essential role in ERBB3 signaling as a positive regulator for tumorigenesis, warranting future development of therapeutic strategies for ERBB3-driven gastric cancer.
|
26942872 |
2016 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The role of HER3 in tumorigenesis has now been recognized, particularly in head and neck squamous cell carcinomas (HNSCCs).
|
26835877 |
2016 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, our data indicate that increased expression of erbB3 plays a pivotal role in activating downstream PI-3K/Akt pathway and promoting erbB2-driven mammary/breast tumorigenesis.
|
26261492 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Deletion of Erbb3 at the time of induction of mutant EGFR had no effect on tumorigenesis, demonstrating that ERBB3 is not required to initiate tumorigenesis.
|
25596284 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To analyze the function of ERBB3 during tumorigenesis, we employed the established DMBA/TPA multi-stage chemical carcinogenesis protocol.
|
26194695 |
2015 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Also, the data suggest that ERBB3 is altered in GC and CRC by various ways, including somatic mutations and increased expression that might play roles in tumorigenesis.
|
24909266 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inhibition of HER3 expression may therefore represent a rational therapeutic approach to breast cancers where HER2/HER3-mediated signaling plays a role in tumorigenesis and progression. miRNAs exerts important roles in regulating gene expressions by binding to and repressing target mRNAs.
|
25046105 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HER-3 is closely related to tumorigenesis, progression and metastasis.
|
24084886 |
2013 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In breast cancer cell lines, shRNA-mediated knockdown of GRHL2 expression or functional inactivation of GRHL2 using dominant negative GRHL2 proteins induces down-regulation of ERBB3 gene expression, a striking reduction in cell proliferation, and morphological and phenotypical alterations characteristic of an epithelial-to-mesenchymal transition (EMT), thus implying contradictory roles of GRHL2 in breast carcinogenesis.
|
23814079 |
2013 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations in ERBB3 drive tumorigenesis.
|
23847370 |
2013 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
ErbB3 is an important regulator of tumorigenesis and is implicated in development of resistance to several currently used oncology drugs.
|
22553357 |
2012 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EGFR, HER3 and HER4 but not HER2 are associated with penile carcinogenesis.
|
21407808 |
2011 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
However, accumulating data provide evidence for the significance of HER3 and HER4 alterations in breast carcinogenesis.
|
19481955 |
2010 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Understanding the role of HER3 in oncogenesis as well as its place as a target for anticancer therapy is an ongoing area of research.
|
20695834 |
2010 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The convergence of structural, mechanistic, and experimental evidence highlighting HER3 functions that may be critical in tumorigenesis have now led to renewed efforts towards identification of cancers or subtypes of cancers wherein HER3 function may be important in tumor progression or drug resistance.
|
20816829 |
2010 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this study, we develop a stable isogenic model of ErbB3 expression in an attempt to decipher ErbB3's true contribution to pancreatic cancer tumorigenesis and to examine how this receptor affects cellular sensitivity to EGFR-targeted therapy.
|
20647770 |
2010 |